Skip to main content
BCRX
NASDAQ Life Sciences

BioCryst 10-Q Details Q3 Profit, $375M Liquidity and Specialty Pharmacy Inventory Boost

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$8.24
Mkt Cap
$2.106B
52W Low
$6.23
52W High
$11.22
52W Position info
32% above low
Off High info
27% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

BCRX sits 32% above its 52-week low of $6.23 on elevated volume (2.2× avg).

Summary

BioCryst's Q3 10-Q backs up the $180.3 million revenue and $37.9 million profit already reported, but flags that the new specialty pharmacy's initial inventory build added an amount in the upper teens of millions to revenue. Liquidity stands at $375.0 million with positive operating cash flow of $75.5 million.


Key Events · Earnings and Guidance · BCRX

  • Q3 Revenue and Profit Confirmed

    Total revenues were $180.292 million versus $159.395 million a year earlier, with net income of $37.916 million ($0.15 basic, $0.14 diluted per share).

  • Specialty Pharmacy Inventory Inflated Q3

    The new sole-source specialty pharmacy's initial inventory position contributed revenue 'in the upper teens of millions of dollars' in Q3; inventory at the pharmacy was at the low end of the required 7-21 day range at quarter end.

  • Nine-Month Loss Is Non-Cash

    The $605.501 million nine-month net loss includes a $697.761 million non-cash acquired IPR&D charge for navenibart from the Astria merger; operating cash flow was positive $75.534 million.

  • Liquidity and Blackstone Debt

    Cash, cash equivalents and investments totaled $374.998 million at September 30, 2026, alongside $400 million of Blackstone term loans maturing January 23, 2031; management says resources fund operations for at least 12 months.


Analysis · BCRX · Life Sciences

The quarter's headline numbers were already out this morning, but the 10-Q is where the quality of the beat becomes visible. Roughly the upper teens of millions of dollars of Q3 product revenue came from the new specialty pharmacy stocking 7-21 days of ORLADEYO inventory, not from underlying patient demand — a one-time channel fill that will not repeat and could even reverse if inventory ordering normalizes. Against that, the nine-month GAAP loss of $605.5 million is almost entirely the $697.8 million non-cash IPR&D write-off from the Astria/navenibart deal, not cash burn; operating cash flow was positive $75.5 million. Liquidity of $375.0 million plus the $400 million Blackstone term loan funded the Astria cash consideration, and management states resources cover at least the next 12 months. The restructuring (Birmingham closure, $16.6 million of charges, plus a September workforce reduction) shows the cost side being reshaped around ORLADEYO and external innovation.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BCRX was trading at $8.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $6.23 to $11.22. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BCRX - Latest Insights

BCRX
Nov 04, 2026, 7:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.66
Real-time Price: $7.59 info
Change: -$1.07 (-12%) info
Market Cap: $1.953B info
BCRX
Nov 04, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $8.52
Real-time Price: $7.59 info
Change: -$0.930 (-11%) info
Market Cap: $1.953B info
BCRX
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $8.02
Real-time Price: $7.59 info
Change: -$0.4285 (-5%) info
Market Cap: $1.953B info
BCRX
Aug 25, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.65
Real-time Price: $7.59 info
Change: -$2.06 (-21%) info
Market Cap: $1.953B info
BCRX
Aug 05, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.65
Real-time Price: $7.59 info
Change: -$2.06 (-21%) info
Market Cap: $1.953B info